BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

RxKinetix, Inc. Receives University of Colorado Technology Transfer Life Sciences Company Of The Year Award


1/13/2006 10:21:47 AM

LOUISVILLE, Colo., Jan. 12 /PRNewswire/ -- RxKinetix, Inc., a specialty pharmaceutical company developing new therapeutics focused in oncology care, today announced that the Company has been awarded the Life Sciences Company of the Year Award by the University of Colorado Technology Transfer Office.

RxKinetix holds license to two technologies from the University License Equity Holdings, Inc. relating to drug delivery. The Company recently completed a successful Phase 2 clinical trial for its lead product, RK-0202 for treatment of oral mucositis in head and neck cancer patients. "We are honored to receive this award from the University of Colorado Technology Transfer Office. It is a wonderful endorsement of our on-going success and recognition of the excellent work of all the employees of RxKinetix," said Harry Ross M. D., chairman and CEO of RxKinetix.

"RxKinetix' successful Phase 2 clinical trial for RK-0202 made it an obvious choice for this award. It is always gratifying to see success from a company founded on technology from the University of Colorado," said David Allen, Associate Vice President for Technology Transfer, University of Colorado.

RxKinetix, Inc. is a specialty pharmaceutical company developing new therapeutics focused in oncology care. Using proven pharmaceuticals and proprietary polymer-based drug delivery technologies, RxKinetix creates new drugs or enhances existing drugs. The Company's strategy improves timelines and reduces risk during clinical development. RxKinetix has a strong intellectual property portfolio in support of its products and technologies. More information regarding RxKinetix is available at www.rxkinetix.com.

RxKinetix, Inc.

CONTACT: Joanna Money, Ph.D., Vice President, Corporate Development ofRxKinetix, Inc., +1-303-926-1900, jmoney@rxkinetix.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES